|
|
Nelfinavir (Viracept) Research
- ACTG 384 Substudy: DEXA Outcomes in Antiretroviral-Naive Patients Randomized to Efavirenz or Nelfinavir or Both Plus Nucleoside Backbone (August 16, 2006)
In XVI International AIDS Conference
- Nelfinavir, Lopinavir/Ritonavir Appear Safe for Hepatitis C Patients (February 10, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Nevirapine Inexpensive, Long-Lasting Option in Preventing Mother-to-Child HIV Transmission, Study Says (September 12, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens Versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease (September 1, 2003)
Patients with advanced HIV are found to benefit the most from HAART regimens containing efavirenz (Sustiva), as opposed to regimens containing nelfinavir (Viracept) or no NNRTI at all.
In Journal of Infectious Diseases
- Combivir + Abacavir Better Tolerated and More Potent Than Combivir + Nelfinavir (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Trizivir Causes Lowest Triglycerides Rise in Comparison With Combivir + Nelfinavir or d4T (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Comparative Incidence and Temporal Accumulation of PI and NRTI Resistance in HIV-Infected Subjects Receiving Lopinavir/Ritonavir or Nelfinavir as Initial Therapy (February 11, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Managing Nelfinavir-Related Diarrhea (January 2003)
Research from the 2002 International AIDS Conference.
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Viral Adaptation to Nelfinavir (January/February 2003)
The first reported evidence of drug-dependent enhancement of HIV replication.
In TAGline, from Treatment Action Group
- Low-Dose Ritonavir Moderately Enhances Nelfinavir Exposure (October 2002)
An abstract from Clinical Pharmacology & Therapeutics.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- The Viramune Hepatic Safety Project: Analysis of Symptomatic Hepatic Events (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Antiretrovirals Concomitantly With Methadone for Hepatitis C Co-Infections (March/April 2002)
Multi-site study finds nelfinavir-based regimen effective in HIV/HCV opiate-addicted patients.
In Body Positive, from Body Positive
- Atazanavir Outperforms Nelfinavir at 48 Weeks of Therapy (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Clinical Experience of Amprenavir (APV) Following Nelfinavir (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Abacavir/Combivir/Nelfinavir, or Lamivudine/Stavudine/NFV (GSK Protocol ESS40002) (October 26, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Differential In Vitro Effects of Indinavir, Nelfinavir and Amprenavir On Cell Differentiation, Insulin Sensitivity and Apoptosis in an Adapted Adipose Cell Model -- Preventive Impact of Rosiglitazone (October 25, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Nelfinavir, Efavirenz, or Both After the Failure of Nucleoside Treatment of HIV Infection (August 9, 2001)
In New England Journal of Medicine
- Final 12-Month Results From the COMBINE Study: A Randomized, Open, Multicenter Trial Comparing Combivir Plus Nelfinavir or Nevirapine in Naive Patients (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Therapeutic Drug Monitoring (TDM) of Nelfinavir (NFV) and Indinavir (IDV) In Treatment-Naive Patients Improves Therapeutic Outcome After 1 Year: Results from ATHENA (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Head-to-Head Study of Two Protease Inhibitors (March 2001)
To read PDF, click here
In Project Inform Perspective, from Project Inform
- A Randomized, Open, Multicenter Trial Comparing Combivir Plus Nelfinavir or Nevirapine in HIV-Infected Naive Patients (The Combine Study) (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- More Data on the Comparative Efficacy of Protease Inhibitors Versus Non-nukes (October 10, 2000)
STEP's coverage of the 40th ICAAC Conference.
In STEP Ezine, from Seattle Treatment Education Project
- Patient Adherence With Twice-Daily Dosing of Nelfinavir Equivalent to NNRTIs When Given in Combination With Dual NRTIs (July 13, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Effect of Change From TID to BID Nelfinavir (NFV) on Viral Load, CD4 Count and Adherence (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Efficacy of Protease Inhibitor Switching to Nevirapine in Patients on HAART with Undetectable Viral Load (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Long-Term Comparative Outcomes of Indinavir (IDV) vs. Nelfinavir (NFV)-Based HAART in Naive Patients in Routine Clinical Practice (July 12, 2000)
The Body's Coverage of the XIII International AIDS Conference.
In The XIII International AIDS Conference, from The Body PRO
- Virologic Response to Indinavir (IDV), Efavirenz (EFV) and Adefovir (ADV) Among Patients Failing Nelfinavir (NFV) (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Ritonavir/Saquinavir as an Alternative for Patients Who Fail Nelfinavir (August 1999)
In HIV Newsline, from San Francisco General Hospital
- Co-Administration of Indinavir 1200 mg with Nelfinavir 1250 mg in a Twice Daily Regimen: Preliminary Safety, PK Activity (February 2, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Co-Administration of Indinavir 1,200 mg (IDV) and Nelfinavir (NFV) 1,250 mg in a Twice Daily Regimen: Preliminary Safety, Pharmacokinetic (PK) and Anti-Viral Activity (November 14, 1998)
In The 36th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- A Study in HIV Positive Women of Quadruple Therapy: Nelfinavir, Saquinavir, Stavudine, and Lamivudine (February 4, 1998)
From Seattle Treatment Education Project
- An Early Look at b.i.d. Dosing Regimens for Nelfinavir (February 3, 1998)
From Seattle Treatment Education Project
- Can Nelfinavir Substitute for Other Protease Inhibitors in Persons With Plasma HIV-1 RNA Below 500 copies/ml Before the Substitution? (February 3, 1998)
From Seattle Treatment Education Project
- Nelfinavir Combination Therapy: Ten-Month Report (April 1997)
From AIDS Treatment News
- Nelfinavir Resistance Appears to Be by a Unique Mutation (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
|
|
